Cargando…
Lethal activity of BRD4 PROTAC degrader QCA570 against bladder cancer cells
Bladder cancer is the most common malignancy of the urinary system. Efforts to identify innovative and effective therapies for bladder cancer are urgently needed. Recent studies have identified the BRD4 protein as the critical factor in regulation of cell proliferation and apoptosis in bladder cance...
Autores principales: | Wang, Qiang, Li, Baohu, Zhang, Wenkai, Li, Zhuoyue, Jiang, Bo, Hou, Sichuan, Ma, Shumin, Qin, Chong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887192/ https://www.ncbi.nlm.nih.gov/pubmed/36733715 http://dx.doi.org/10.3389/fchem.2023.1121724 |
Ejemplares similares
-
The therapeutic effect of the BRD4-degrading PROTAC A1874 in human colon cancer cells
por: Qin, An-cheng, et al.
Publicado: (2020) -
Targeting Protein Kinases Degradation by PROTACs
por: Yu, Fei, et al.
Publicado: (2021) -
Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs)
por: Zhang, Qisi, et al.
Publicado: (2022) -
Antibody–PROTAC Conjugates Enable HER2-Dependent
Targeted Protein Degradation of BRD4
por: Maneiro, María, et al.
Publicado: (2020) -
Enhanced anti-glioma efficacy of doxorubicin with BRD4 PROTAC degrader using targeted nanoparticles
por: He, Yihong, et al.
Publicado: (2022)